Hyderabad pharma maker of complex generics, oncology drugs and APIs, plus a Crop Health Sciences agrochem arm.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
| Reserves | 3.7k | 4.1k | 4.2k | 4.8k | 5.8k | 7.6k | 8.6k | 9.2k |
| Borrowings | 316 | 268 | 416 | 167 | 371 | 279 | 261 | 714 |
| Other Liabilities | 498 | 403 | 430 | 617 | 682 | 744 | 1.5k | 1.1k |
| Total Liabilities | 4.6k | 4.8k | 5.1k | 5.7k | 6.9k | 8.6k | 10.4k | 11.1k |
| AssetsFixed Assets | 1.6k | 2.0k | 2.3k | 2.4k | 2.5k | 2.7k | 2.7k | 2.8k |
| CWIP | 518 | 223 | 130 | 64 | 137 | 225 | 255 | 294 |
| Investments | 112 | 304 | 308 | 392 | 539 | 474 | 774 | 3.1k |
| Other Assets | 2.4k | 2.2k | 2.4k | 2.8k | 3.7k | 5.2k | 6.7k | 4.8k |
| Total Assets | 4.6k | 4.8k | 5.1k | 5.7k | 6.9k | 8.6k | 10.4k | 11.1k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 669 | 417 | 299 | 46 | 849 | 1.2k | 1.7k | 1.8k |
| Cash from Investing | -611 | -175 | -107 | 4 | -465 | -1.0k | -1.4k | -2.1k |
| Cash from Financing | -51 | -251 | -186 | 35 | -363 | -247 | -211 | 298 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 225 | 81 | 92 | -142 | 674 | 855 | 1.3k | 1.4k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (12.3×) and current (11.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 25.6% growth and a 12× exit, ₹945 only delivers your return if you pay ₹1,371. The price is currently baking in 17% growth.
EPS grows 25.6%/yr for 5 years, then fades to 6% over 2, exits at 12×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 25.6% | 99.48 |
| FY28 | 25.6% | 124.94 |
| FY29 | 25.6% | 156.93 |
| FY30 | 25.6% | 197.10 |
| FY31 | 25.6% | 247.56 |
| FY32 | 15.8% ·fade | 286.67 |
| FY33 | 6.0% ·fade | 303.87 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.